|
4basebio PLC - Cambridge, England-based life sciences company - Appoints Scott Lorimer as chief operating officer, with immediate effect. This follows the appointment last week of Christine Wolosin as chief commercial officer, and of Amy Walker last month as chief executive. 4basebio says he will be responsible for scaling its synthetic DNA platform to serve its client base in the cell and gene therapy, mRNA, and vaccine markets. He will also oversee manufacturing operations, quality and regulatory compliance, process development, and supply chain and facility management. Lorimer comments: ‘I have spent my career developing technical and manufacturing capabilities for advanced therapies and 4basebio offers the perfect opportunity to join a dynamic, fast-growing and commercially-focused company leading the revolution in synthetic DNA. The company is at a tipping point with an expansion of facilities well underway, scaling operations to meet increasing customer demand for its synthetic DNA products, and I’m looking forward to joining Amy and the team in transitioning the business for a period of increased commercial growth.’ Current stock price: 550.00 pence each 12-month change: down 51% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
